Endoscopic treatment of esophagogastric varices in cirrhosis

doi:10.3969/j.issn.1004-583X.2018.11.003

Abstract

Abstract: Variceal bleeding in cirrhosis is a lifethreatening complication of portal hypertension. The primary prophylaxis strategy of esophageal varices is nonselective betablockers (NSBBs) or endoscopic variceal ligation (EVL). EVL is the first choice for acute esophageal varices bleeding. The combination of NSBBs and EVL is the recommended management in the secondary prophylaxis. For gastric varices bleeding, gastroesophageal varices type 1 (GOV1) is recommended for EVL, gastroesophageal varices type 2 (GOV2) and isolated gastric varices (IGV) are recommended for endoscopic tissue glue injection. In the prevention of gastric varices rebleeding, transjugular intrahepatic portosystemic shunt (TIPS) can be applied to GOV2 and IGV, and EVL, NSBBs or endoscopic tissue glue injection can be applied to GOV1. NSBBs or endoscopic tissue glue injection can be used for primary prophylaxis of gastric varices.

Key words: liver cirrhosis, esophageal and gastric varices, endoscopic variceal ligation, endoscopic injection sclerotherapy, endoscopic tissue glue injection

Yin Kaige, Jin Xiaoxu, Feng Zhijie. Endoscopic treatment of esophagogastric varices in cirrhosis[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2018.11.003.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2018.11.003

https://huicui.hebmu.edu.cn/EN/Y2018/V33/I11/929

[1]	Cheng Mingrong, Dai Dejian. Efficacy of Zhenqi Fuzheng Capsule combined with ursodeoxycholic acid on primary biliary cholangitis and its impact on thyroid function [J]. Clinical Focus, 2020, 35(3): 260-263.
[2]	Huang Guangming, Gu Dahui, Hao Yaqin, He Zhijun. Effect of nutritional status on clinical outcomes in elderly patients with hepatic cirrhosis [J]. Clinical Focus, 2019, 34(2): 128-131.
[3]	Wang Yankun1， Ma Junji2, Zhang Ming2. Role of cytokeratin 7 in pathological diagnosis of liver cirrhosis [J]. Clinical Focus, 2019, 34(2): 124-127.
[4]	Jin Yan, Ge Zhihua, Sun Yuanyuan, Xu Shuyan, Shao Jianguo. Clinical study of AIMS65 score for risk assessment of esophagealgastric variceal bleeding in liver cirrhosis [J]. Clinical Focus, 2018, 33(6): 498-501.
[5]	Zhao Wen， Zhang Siyu， Lu Yu， Zhao Suxian， Wang Rongqi， Nan Yuemin. FibroTouch combined with FIB-4， APRI and GPRI in diagnosis of liver fibrosis [J]. Clinical Focus, 2018, 33(2): 140-144.
[6]	Xu Manman1, Cheng Kailiang2, Qiu Qian3, Zhao Xinyu2, Duan Zhongping1, Wang Li2, Chen Yu1. Factors associated with adherence to antiviral therapy in patients with HBV-related cirrhosis [J]. Clinical Focus, 2018, 33(11): 950-955.
[7]	Yang Xincheng, Jin Xiaoxu, Yao Jinfeng. Research advances of portal vein thrombosis in liver cirrhosis [J]. Clinical Focus, 2018, 33(11): 947-949，955.
[8]	Chen Lei, Zhang Xueqiang. Role of transjugular intrahepatic portosystemic shunt in management of portal hypertension [J]. Clinical Focus, 2018, 33(11): 938-941.
[9]	Cheng Ran, Xu Xiaoyuan. Diagnosis and therapy of ascites in liver cirrhosis [J]. Clinical Focus, 2018, 33(11): 921-924.
[10]	Kong Ming， Shi Hongbo， Bai Li， Yao Jia， Chen Yu， Duan Zhongping. Characteristics of plasma amino acids in patients with HBVrelated chronic hepatitis， cirrhosis and acute on chronic liver failure [J]. Clinical Focus, 2016, 31(7): 732-735,740.
[11]	Wei Xinliang， Wei Sichen， Tian Shuying， Kong Yu， Wang Weiwei， Jiang Hongyu. Correlation analysis and clinical significance of serum omentin and adiponectin in patients with liver cirrhosis [J]. Clinical Focus, 2016, 31(12): 1313-1317.
[12]	Zhao Zhengbin1a，Fan Wenhai1b， Chen Qingfeng2，Yao Liqiong1a. Analysis of pathogen distribution and drug resistance in liver cirrhosis patient with spontaneous bacterial peritonitis [J]. Clinical Focus, 2016, 31(11): 1222-1224,1228.
[13]	Wang Qingli;Yang Lin;Liu Qi. Clinical observation on effect of coffeic acid on leukocyte anal platelet count in patients with cirrhosis [J]. Clinical Focus, 2015, 30(9): 1027-1.0281e+007.
[14]	Ge Xiuzhen;Wang Yuming;Zheng Zhongqing;Wang Tao;Wang Bangmao. Risk factors in poor prognosis after endoscopic variceal ligation and endoscopic injection sclerotherapy of esophageal varices caused by liver cirrhosis [J]. Clinical Focus, 2015, 30(3): 250-252256.
[15]	LIU Ya;WU Jin-ming;CHEN Mei-qin. Efficacy of entecavir for 96 weeks in patients with hepatitis B virus-related cirrhosis and chronic hepatitis B [J]. Clinical Focus, 2014, 29(6): 672-675.

Endoscopic treatment of esophagogastric varices in cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments